Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Net Income (2016 - 2025)

Avalo Therapeutics' Net Income history spans 11 years, with the latest figure at -$13.7 million for Q4 2025.

  • For Q4 2025, Net Income rose 61.18% year-over-year to -$13.7 million; the TTM value through Dec 2025 reached -$78.3 million, down 122.78%, while the annual FY2025 figure was -$78.3 million, 122.78% down from the prior year.
  • Net Income reached -$13.7 million in Q4 2025 per AVTX's latest filing, up from -$30.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
  • Average Net Income over 4 years is -$9.1 million, with a median of -$8.2 million recorded in 2023.
  • The largest YoY upside for Net Income was 1301.79% in 2024 against a maximum downside of 1118.38% in 2024.
  • A 4-year view of Net Income shows it stood at -$65000.0 in 2021, then plummeted by 12466.15% to -$8.2 million in 2023, then crashed by 332.65% to -$35.3 million in 2024, then skyrocketed by 61.18% to -$13.7 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Net Income are -$13.7 million (Q4 2025), -$30.6 million (Q3 2025), and -$20.8 million (Q2 2025).